Phenotypes Associated with This Genotype

Genotype
MGI:3716404

• Allelic Composition: Kras^tm4Tyj/Kras⁺
• Genetic Background: involves: 129S4/SvJae

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased lung tumor incidence ( J:119477 , J:216266 , J:299900 )

• treatment with adenoviral Cre to induce oncogenic Kras expression results in lung tumor development, but causes a lower tumor burden and decreased overall tumor area compared to induced mutants on a Spry2-null background (J:119477)

• 20% and 100% of mice develop lung lesions at 6 weeks and 20 weeks, respectively, post intranasal adenoviral cre administration (J:216266)

• all mice delivered with an adenovirus expressing cre recombinase through nasal inhalation at 8 weeks of age develop lung tumors (J:299900)

increased lung adenoma incidence ( J:207982 , J:333347 )

• mice develop lung adenomas with a few adenocarcinomas following intratracheal administration of an adenovirus expressing Cre (Ad-Cre) (J:207982)

• treatment with MLN4924, a small molecular inhibitor of NAE, beginning at 13 weeks after Ad-Cre administration reduces tumor burden, with a reduction in both number of hyperplastic areas and adenomas and size of the tumors (J:207982)

• mice intratracheally administered an adenovirus expressing cre recombinase (Ad-cre) develop multiple lung adenomas (J:333347)

increased lung adenocarcinoma incidence ( J:207982 , J:333347 )

• a few adenocarcinomas develop in mice following Ad-Cre administration (J:207982)

• mice intratracheally administered Ad-cre develop a few adenocarcinomas (J:333347)

respiratory system

increased lung tumor incidence ( J:119477 , J:216266 , J:299900 )

• treatment with adenoviral Cre to induce oncogenic Kras expression results in lung tumor development, but causes a lower tumor burden and decreased overall tumor area compared to induced mutants on a Spry2-null background (J:119477)

• 20% and 100% of mice develop lung lesions at 6 weeks and 20 weeks, respectively, post intranasal adenoviral cre administration (J:216266)

• all mice delivered with an adenovirus expressing cre recombinase through nasal inhalation at 8 weeks of age develop lung tumors (J:299900)

increased lung adenoma incidence ( J:207982 , J:333347 )

• mice develop lung adenomas with a few adenocarcinomas following intratracheal administration of an adenovirus expressing Cre (Ad-Cre) (J:207982)

• treatment with MLN4924, a small molecular inhibitor of NAE, beginning at 13 weeks after Ad-Cre administration reduces tumor burden, with a reduction in both number of hyperplastic areas and adenomas and size of the tumors (J:207982)

• mice intratracheally administered an adenovirus expressing cre recombinase (Ad-cre) develop multiple lung adenomas (J:333347)

increased lung adenocarcinoma incidence ( J:207982 , J:333347 )

• a few adenocarcinomas develop in mice following Ad-Cre administration (J:207982)

• mice intratracheally administered Ad-cre develop a few adenocarcinomas (J:333347)

mortality/aging

decreased tumor-free survival time ( J:333347 )

• mice intratracheally administered Ad-cre have a median survival time of approximately 130 days with 100% death by 175 days

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:207982